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R EV E A L 55-center observational, US-based study, provides information on current demographic, clinical, and treatment patterns in patients with PAH. To determine if patients who improve from functional class (FC) III at enrollment to FC I/II at follow-up assessment have a better survival rate compared with patients who remain stable FC III, two-year outcomes were analyzed.
1,082 adult patients who were enrolled in REVEAL and were assessed as FC III at enrollment (based on the most recent Methods: pre-enrollment evaluation) and had at least one follow-up FC assessment within the first year after enrollment were included in these analyses. We classified patients as: 1) improved if FC III improved to FC I/II; 2) stable if remained FC III; or 3) deteriorated if worsened to FC IV (based on their first FC follow-up assessment after enrollment). We compared the survival rates (estimates +/-SE) of these three subgroups from the time of the first follow-up FC assessment based on the log-rank test.
Demographics and clinical characteristics of FC III patients at enrollment who improved to FC I/II, remained stable at FC III, or Results: deteriorated at their first follow-up assessment are presented in the Table. Twenty-six percent (n = 281) improved, 66% (n = 718) remained stable and 8% (n = 83) deteriorated. Kaplan-Meier survival from first follow-up FC assessment in these subgroups are presented in the Figure; two-year survival rates were 88 ± 2%, 76 ± 2%, and 34 ± 6%, for FC I/II, FC III, and FC IV patients, respectively ( <0.001 for all P pairwise comparisons). Results are similar for both newly and previously diagnosed patients (i.e., confirmatory right heart catheterization within or not within 3 months prior to enrollment) who were FC III at enrollment.
These results suggest that patients who improve from FC III to FC I/II have a better two-year survival compared with patients Conclusions: who remain FC III. 
Group I PAH Diagnosis at Enrollment, n (%) c
Idiopathic 131 (47) 353 (49) 41 ( 
